1. Home
  2. ALT vs ACTG Comparison

ALT vs ACTG Comparison

Compare ALT & ACTG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALT
  • ACTG
  • Stock Information
  • Founded
  • ALT 1997
  • ACTG 1993
  • Country
  • ALT United States
  • ACTG United States
  • Employees
  • ALT N/A
  • ACTG N/A
  • Industry
  • ALT Biotechnology: Pharmaceutical Preparations
  • ACTG Multi-Sector Companies
  • Sector
  • ALT Health Care
  • ACTG Miscellaneous
  • Exchange
  • ALT Nasdaq
  • ACTG Nasdaq
  • Market Cap
  • ALT 327.4M
  • ACTG 314.4M
  • IPO Year
  • ALT N/A
  • ACTG 1996
  • Fundamental
  • Price
  • ALT $3.57
  • ACTG $3.31
  • Analyst Decision
  • ALT Strong Buy
  • ACTG
  • Analyst Count
  • ALT 6
  • ACTG 0
  • Target Price
  • ALT $17.40
  • ACTG N/A
  • AVG Volume (30 Days)
  • ALT 2.3M
  • ACTG 182.0K
  • Earning Date
  • ALT 11-11-2025
  • ACTG 11-11-2025
  • Dividend Yield
  • ALT N/A
  • ACTG N/A
  • EPS Growth
  • ALT N/A
  • ACTG N/A
  • EPS
  • ALT N/A
  • ACTG N/A
  • Revenue
  • ALT $20,000.00
  • ACTG $247,813,000.00
  • Revenue This Year
  • ALT N/A
  • ACTG $109.86
  • Revenue Next Year
  • ALT $761,880.20
  • ACTG N/A
  • P/E Ratio
  • ALT N/A
  • ACTG N/A
  • Revenue Growth
  • ALT N/A
  • ACTG 62.44
  • 52 Week Low
  • ALT $2.90
  • ACTG $2.70
  • 52 Week High
  • ALT $11.16
  • ACTG $5.36
  • Technical
  • Relative Strength Index (RSI)
  • ALT 44.06
  • ACTG 48.23
  • Support Level
  • ALT $3.54
  • ACTG $3.13
  • Resistance Level
  • ALT $3.72
  • ACTG $3.40
  • Average True Range (ATR)
  • ALT 0.16
  • ACTG 0.13
  • MACD
  • ALT 0.01
  • ACTG 0.02
  • Stochastic Oscillator
  • ALT 10.94
  • ACTG 47.37

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

About ACTG Acacia Research Corporation (Acacia Tech)

Acacia Research Corp is focused on acquiring and operating businesses across the industrial, energy, and technology sectors where it believes it can leverage its expertise, capital base, and deep industry relationships to drive value. The company has four reportable business segments: Intellectual Property Operations, Industrial Operations, Energy Operations and Manufacturing Operations. It derives revenue from Intellectual Property Operations segment. Geographically, it operates in Americas, Europe, Middle East and Africa, China, India, and Asia-Pacific, excluding China and India.

Share on Social Networks: